Taysha falls on wider-than-expected quarterly loss
TSHA•Shares fall after larger quarterly loss
- Shares of Taysha Gene Therapies
TSHA.Ofell 8.7% to $6.10 premarket. - The company reported a second-quarter net loss of $46.6 million versus analysts' average loss estimate of $42.7 million, according to LSEG data.
TSHA's R&D expenses were $38.6 million for the three months ended June 30, compared with $20.1 million a year ago.- The company said it is spending more on manufacturing and trials as it prepares for the potential launch of its therapies.
- The company's experimental therapy TSHA-102 is being developed for the treatment of Rett syndrome, a rare genetic neurodevelopmental disorder that mostly affects girls.
- As of the last close, the stock was up 21.5% year to date.
